A | B | C | D | E | F | G | H | CH | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9
![]() | |
Clinical data | |
---|---|
Other names | NSC-43194; 4-Dehydrostanozolol; 17α-Methyl-2'H-androsta-2,4-dienopyrazol-17β-ol |
Routes of administration | By mouth |
Drug class | Androgen; Anabolic steroid |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H30N2O |
Molar mass | 326.484 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Hydroxystenozole (INN ), also known as 17α-methylandrost-4-enopyrazol-17β-ol, is an orally active androgen/anabolic steroid (AAS) and a 17α-alkylated derivative of testosterone that was described in the literature in 1967 but was never marketed.[1] It is closely related to stanozolol (17α-methyl-5α-androstanopyrazol-17β-ol), differing from it only in hydrogenation (i.e., double bonds and their placement).[1]
References
- ^ a b Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 668. ISBN 978-1-4757-2085-3.
>Text je dostupný pod licencí Creative Commons Uveďte autora – Zachovejte licenci, případně za dalších podmínek. Podrobnosti naleznete na stránce Podmínky užití.
Text je dostupný za podmienok Creative
Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších
podmienok.
Podrobnejšie informácie nájdete na stránke Podmienky
použitia.